Pharmacokinetics, Safety, and Tolerability of CSL760, an Intravenous Anti-SARS-CoV-2 Hyperimmune Globulin, in Healthy Adult Subjects

Clinical trial NCT04638634 · TERMINATED

Trial details

NCT number: NCT04638634
Sponsor: CSL Behring
Status: TERMINATED
Phase: Phase 1
Study type: INTERVENTIONAL

Coronavirus Disease 2019 (COVID-19)

Start date: 2021-02-02
Primary completion: 2021-06-09
Enrollment: 12

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.